Skip to main content

Table 3 Change of neurocognitive function (NCF) test at seven months from baseline

From: Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment

  Mean change from Baseline (%)a 95% CI Probability of deteriorationb(%)
MMSE − 1.2 − 9.8 to 7.4 3.8
SVLT-Total recall −7.7 −19.6 to 4.2 7.7
SVLT-Delayed recall −9.2c − 25.4 to 7.0c 7.7
SVLT-Recognition −3.4 −12.7 to 5.8 11.5
RCFT-COPY 1.8 −7.4 to 11.1 24
RCFT-Immediate recall −8.1 −36.2 to 20.0 8
RCFT-Delayed recall −25.2d − 52.8 to 2.5d 8
RCFT-Recognition −3.8 −11.2 to 4.0 12
  1. MMSE Mini-Mental State Examination, SVLT Seoul Verbal Learning Test, RCFT Rey Complex Figure Test and Recognition Trial
  2. aΔNCF = (NCFB-NCFF)/NCFB, Where B = baseline and F = follow-up, (Minus change indicate improved NCF)
  3. bDeterioration in NCF test from baseline defined as drop of z-score 1.5 (drop of 1.5 standard deviation)
  4. cExclusion of one patient with 0 test result at baseline
  5. dExclusion of one patient who could not be assessed at baseline